SAN Stock Analysis: Sanofi | PA
Drug Manufacturers - General | PA, France | Market Cap: 87.183m EUR | 12M Return: -1.6% | FR0000120578 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 162M
EPS Trend: -2.8%
Qual. Beats: 1
Rev. Trend: 69.1%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, founded in 1994 (formerly Sanofi-Aventis until 2011). It operates across the full pharmaceutical value chain-from research and development through manufacturing and commercialization-spanning immunology and inflammation, rare diseases (including neurology), oncology, and a broad vaccines portfolio covering pediatric indications (polio, pertussis, Hib) as well as RSV, hepatitis A, typhoid, yellow fever, and rabies. The company pursues an externally-sourced innovation strategy, maintaining numerous collaboration and licensing agreements with biotech partners such as Exscientia, ABL Bio, Innate Pharma, Kymera Therapeutics, Nurix Therapeutics, Denali Therapeutics, and Scribe Therapeutics, among others. The pharmaceutical sector is characterized by high R&D intensity, heavy reliance on intellectual property protection, and increasing use of partnerships and AI-driven discovery platforms to supplement in-house pipelines and offset patent expirations.
- Dupixent franchise sales accelerate across atopic dermatitis and asthma indications
- Vaccines segment revenue normalizes as pediatric demand softens post-pandemic
- R&D pipeline partnerships expand oncology and immunology development pipeline
| Net Income: 6.76b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -1.69 > 1.0 |
| NWC/Revenue: -0.85% < 20% (prev 16.96%; Δ -17.81% < -1%) |
| CFO/TA 0.12 > 3% & CFO 15.6b > Net Income 6.76b |
| Net Debt (19.1b) to EBITDA (13.8b): 1.39 < 3 |
| Current Ratio: 0.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.20b) vs 12m ago -2.77% < -2% |
| Gross Margin: 65.15% > 18% (prev 71.14%; Δ -5.99% > 0.5%) |
| Asset Turnover: 37.81% > 50% (prev 37.55%; Δ 0.26% > 0%) |
| Interest Coverage Ratio: 10.58 > 6 (EBIT TTM 8.31b / Interest Expense TTM 785.0m) |
| A: -0.00 (Total Current Assets 31.5b - Total Current Liabilities 31.9b) / Total Assets 129b |
| B: 0.52 (Retained Earnings 66.9b / Total Assets 129b) |
| C: 0.07 (EBIT TTM 8.31b / Avg Total Assets 127b) |
| D: 1.16 (Book Value of Equity 69.2b / Total Liabilities 59.5b) |
| Altman-Z'' = 3.33 = A |
| DSRI: 0.10 (Receivables 492.0m/8.21b, Revenue 48.0b/46.9b) |
| GMI: 1.09 (GM 71.14% / 65.15%) |
| AQI: 1.08 (AQ_t 0.66 / AQ_t-1 0.62) |
| SGI: 1.02 (Revenue 48.0b / 46.9b) |
| TATA: -0.07 (NI 6.76b - CFO 15.6b) / TA 129b) |
| Beneish M = -3.63 (Cap -4..+1) = AAA |
As of August 08, 2026, the stock is trading at EUR 75.31 with a total of 1,953,360 shares traded. Over the past week, the price has changed by +1.13%, over one month by -0.62%, over three months by +2.13% and over the past year by -1.63%.
Current recommended Stop Loss: 70.60 (which is 6.3% or 2.4 ATR below the current price).
Sanofi has no consensus analysts rating.
P/E Trailing = 18.3763
P/E Forward = 9.2421
P/S = 1.8411
P/B = 1.3138
P/EG = 4.0171
Revenue TTM = 48.0b EUR
EBIT TTM = 8.31b EUR
EBITDA TTM = 13.8b EUR
Long Term Debt = 14.6b EUR (from longTermDebt, last quarter)
Short Term Debt = 7.25b EUR (from shortTermDebt, last quarter)
Debt = 25.5b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.90b
Net Debt = 19.1b EUR (calculated: Debt 25.5b - CCE 6.35b)
Enterprise Value = 106b EUR (87.2b + Debt 25.5b - CCE 6.35b)
Interest Coverage Ratio = 10.58 (Ebit TTM 8.31b / Interest Expense TTM 785.0m)
EV/FCF = 6.61x (Enterprise Value 106b / FCF TTM 16.1b)
FCF Yield = 15.14% (FCF TTM 16.1b / Enterprise Value 106b)
FCF Margin = 33.51% (FCF TTM 16.1b / Revenue TTM 48.0b)
Net Margin = 14.08% (Net Income TTM 6.76b / Revenue TTM 48.0b)
Gross Margin = 65.15% ((Revenue TTM 48.0b - Cost of Revenue TTM 16.7b) / Revenue TTM)
Gross Margin QoQ = 75.47% (prev 72.09%)
Tobins Q-Ratio = 0.82 (Enterprise Value 106b / Total Assets 129b)
Interest Expense / Debt = 3.08% (Interest Expense 785.0m / Debt 25.5b)
Taxrate = 21.64% (1.88b / 8.70b)
NOPAT = 6.51b (EBIT 8.31b * (1 - 21.64%))
Current Ratio = 0.99 (Total Current Assets 31.5b / Total Current Liabilities 31.9b)
Debt / Equity = 0.37 (Debt 25.5b / totalStockholderEquity, last quarter 69.2b)
Debt / EBITDA = 1.39 (Net Debt 19.1b / EBITDA 13.8b)
Debt / FCF = 1.19 (Net Debt 19.1b / FCF TTM 16.1b)
Total Stockholder Equity = 71.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.32% (Net Income 6.76b / Total Assets 129b)
RoE = 9.43% (Net Income TTM 6.76b / Total Stockholder Equity 71.7b)
RoCE = 9.62% (EBIT 8.31b / Capital Employed (Equity 71.7b + L.T.Debt 14.6b))
RoIC = 6.38% (NOPAT 6.51b / Invested Capital 102b)
WACC = 5.05% (E(87.2b)/V(113b) * Re(5.82%) + D(25.5b)/V(113b) * Rd(3.08%) * (1-Tc(0.22)))
Discount Rate = 5.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.84 | Cagr: -1.88%
[DCF] Terminal Value 74.12% ; FCFF base≈16.7b ; Y1≈15.5b ; Y5≈14.0b
[DCF] Fair Price = 169.6 (EV 222b - Net Debt 19.1b = Equity 203b / Shares 1.20b; r=8.35% [WACC [floored]]; 5y FCF grow -9.04% → 2.50% )
EPS Correlation: -2.83 | EPS CAGR: -0.10% | SUE: 1.41 | # QB: 1
Revenue Correlation: 69.09 | Revenue CAGR: 5.13% | SUE: 1.07 | # QB: 1
EPS current Quarter (2026-09-30): EPS=2.65 | Chg30d=-12.20% | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=8.55 | Chg30d=+0.36% | Revisions=+55% | GrowthEPS=+9.2% | GrowthRev=+8.0%
EPS next Year (2027-12-31): EPS=9.07 | Chg30d=+0.59% | Revisions=+50% | GrowthEPS=+6.0% | GrowthRev=+7.2%
[Analyst] Revisions Ratio: +50% (up=15, down=4)